Regeneron Pharmaceuticals (REGN)

REGN Antibody Therapeutics

BiotechSign Signal Grade

C
Signal Grade
51.6/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying
0
Publications
100
Dilution Risk
10
Clinical Activity
100
Short Interest
10

Pipeline Overview

Therapeutic Focus
Antibody Therapeuticssrc

Clinical Trial Activity

216
Clinical Trials
(ClinicalTrials.gov aggregate)
51 Phase 1, 95 Phase 2, 49 Phase 3, 18 Phase 4
Trial Phase Breakdown
5
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-12. ClinicalTrials.gov

Dilution Risk

LOW DILUTION RISK
10/100
Dilution Score
15Warrant Risk
15Convertible Risk
19Offering Ability

Dilution score: 10/100 (LOW), cash runway not available

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

2.20%
Float Shorted
2.5
Days to Cover
LOW
Squeeze Risk
-14.9%
SI Change
DECREASING
Trend
2,150,303
Shares Short

Short interest: 2.2% of float, squeeze risk: LOW

FINRA short sale data. FINRA short interest

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Recent Publications

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Regeneron Pharmaceuticals.

Full REGN Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.